Myelosuppression in patients treated with ¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable

References

• Larson SM, Carrasquillo JA, Cheung NKV, et al. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347–360.
   PubMed Web of Science ®Google Scholar
• Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends. Clin Cancer Res. 2011;17(20):6406–6416.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2021;81(10):1229–2463.
   Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441–449.
   PubMed Web of Science ®Google Scholar
• Jacene HA, Filice R, Kasecamp W, et al. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767–1776.
   PubMed Web of Science ®Google Scholar
• Papadimitroulas P, Loudos G, Nikiforidis GC, et al. A dose point kernel database using GATE Monte Carlo simulation toolkit for nuclear medicine applications: comparison with other Monte Carlo codes. Med Phys. 2012;39(8):5238–5247.
   PubMed Web of Science ®Google Scholar
• Dahle J, Repetto-Llamazares AHV, Mollatt CS, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-cd37 radioimmunoconjugate against non-hodgkin’s lymphoma. Anticancer Res. 2013;33(1):85–96.
   PubMed Web of Science ®Google Scholar
• Zhao X, Tridandapani S, Lehman A, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569–2577.
   PubMed Web of Science ®Google Scholar
• Schwartz-Albiez R, Dörken B, Hofmann W, et al. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140:905–914.
   PubMed Web of Science ®Google Scholar
• Heider K-h, Kiefer K, Zenz T, et al. LYMPHOID NEOPLASIA A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159–4169.
   PubMed Web of Science ®Google Scholar
• Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500–3510.
   PubMed Web of Science ®Google Scholar
• Bertoni F, Stathis A. Staining the target: CD37 expression in lymphomas. Blood. 2016;128(26):3022–3023.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–1981.
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20):4885–4893.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10(11):1696–1711.
   PubMed Web of Science ®Google Scholar
• Hindorf C, Glatting G, Chiesa C, et al. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238–1250.
   PubMed Web of Science ®Google Scholar
• Puvvada SD, Guillén-Rodríguez JM, Yan J, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin®) radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed follicular non-Hodgkin lymphoma: final results of a phase II study. Oncology. 2018;94(5):274–280.
   PubMed Web of Science ®Google Scholar
• Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30(2 Suppl 4):31–38.
   PubMed Web of Science ®Google Scholar
• Walrand S, Barone R, Pauwels S, et al. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 2011;38(7):1270–1280.
   PubMed Web of Science ®Google Scholar
• Buckley SE, Chittenden SJ, Saran FH, et al. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50(9):1518–1524.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001;42:1713–1721.
   PubMed Web of Science ®Google Scholar
• DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131–metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004;22(12):2452–2460.
   PubMed Web of Science ®Google Scholar
• Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2005;32(4):458–469.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Flinn I. Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biother Radiopharm. 2002;17(4):399–403.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Illidge T, Bolstad N, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091–4101.
   PubMed Web of Science ®Google Scholar
• Blakkisrud J, Løndalen A, Dahle J, et al. Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with 177Lu-lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate. J Nucl Med. 2017;58(1):55–61.
   PubMed Web of Science ®Google Scholar
• CTCAE4. Common terminology criteria for adverse events. 4th ed. Bethesda (MD): US National Cancer Institute; 2009.
   Google Scholar
• ICRP. Basic anatomical and physiological data for use in radiological protection – the skeleton. ICRP Publication 70. Ann ICRP. 1995;25(2):1–80.
   Google Scholar
• de Klerk JM, van Dieren EB, van Het Schip AD, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med. 1996;37(1):38–41.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39(1-2):181–194.
   PubMed Web of Science ®Google Scholar
• Wiseman G, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465–474.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Zhang CH, Blumenthal RD, et al. Prediction of hematologic toxicity after radioimmunotherapy with 131-I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999;40(10):1609–1616.
   PubMed Web of Science ®Google Scholar
• Baechler S, Hobbs RF, Jacene HA, et al. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010;51(12):1878–1884.
   PubMed Web of Science ®Google Scholar
• Stokke C, Blakkisrud J, Løndalen A, et al. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging. 2018;45(7):1233–1241.
   PubMed Web of Science ®Google Scholar
• Lassmann M, Flux G, Hindorf C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405–1412.
   PubMed Web of Science ®Google Scholar
• Lassmann M, Eberlein U. The relevance of dosimetry in precision medicine. J Nucl Med. 2018;59(10):1494–1499.
   PubMed Web of Science ®Google Scholar
• Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol. 2001;11(3):197–209.
   PubMed Web of Science ®Google Scholar
• Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480–1489.
   PubMed Web of Science ®Google Scholar
• Heyerdahl H, Repetto-Llamazares AHV, Dahle J. Administration of beta-emitting anti-CD37 radioimmunoconjugate lutetium (177Lu) lilotomab satetraxetan as weekly multiple injections increases maximum tolerated activity in nude mice with non-Hodgkin lymphoma xenografts. GJCT. 2018;4(1):181–190.
   Google Scholar